Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castration-resistant Prostate Cancer Metastatic to Bone”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Early research (Phase 1)Ended earlyNCT03043989
What this trial is testing

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 4
Testing effectiveness (Phase 2)Study completedNCT02507570
What this trial is testing

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Who this might be right for
Prostate Carcinoma Metastatic to the Bone
Carolina Research Professionals, LLC 40
Testing effectiveness (Phase 2)Study completedNCT02649790
What this trial is testing

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Karyopharm Therapeutics Inc 277
Testing effectiveness (Phase 2)Study completedNCT02384382
What this trial is testing

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate Carcinoma Metastatic to the BoneCastration Resistant Prostate Cancer
Pfizer 23
Post-approval studies (Phase 4)Study completedNCT02721433
What this trial is testing

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

Who this might be right for
Breast CancerProstate CancerMetastasis
Ottawa Hospital Research Institute 263
Large-scale testing (Phase 3)Study completedNCT00838201
What this trial is testing

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Who this might be right for
CancerCarcinomaCastrate-Resistant Prostate Cancer+2 more
Amgen 384
Testing effectiveness (Phase 2)UnknownNCT04033432
What this trial is testing

SEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents+7 more
Northwestern University 14
Not applicableLooking for participantsNCT04489719
What this trial is testing

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Prostate Carcinoma+1 more
University of Washington 48
Not applicableStudy completedNCT04681144
What this trial is testing

Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety

Who this might be right for
Prostate Cancer
Bayer 103